[2021年至2022年系统性红斑狼疮的研究进展]
[Research progress in systemic lupus erythematosus from 2021 to 2022].
作者信息
Li Yong-Zhen, Wu Xiao-Chuan
机构信息
Department of Pediatrics, Second Xiangya Hospital, Central South University, Changsha 410000, China.
出版信息
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Aug 15;25(8):785-790. doi: 10.7499/j.issn.1008-8830.2302150.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems, presenting a complex and diverse clinical manifestation. The heterogeneous treatment response and prognosis of SLE pose significant challenges to its diagnosis, classification, and homogeneous treatment. The emergence of new technologies and fields, such as synthetic biology, genomics, and proteomics, has contributed to a deeper exploration of the pathogenesis and biomarkers of SLE, facilitating precision diagnosis and treatment. This review summarizes the latest research data and achievements in SLE for the years 2021-2022, providing an overview and summary of relevant studies conducted in the past two years.
摘要
系统性红斑狼疮（SLE）是一种影响多个器官系统的自身免疫性疾病，临床表现复杂多样。SLE异质性的治疗反应和预后对其诊断、分类及同质化治疗构成了重大挑战。合成生物学、基因组学和蛋白质组学等新技术和领域的出现，有助于更深入地探索SLE的发病机制和生物标志物，推动精准诊断和治疗。本综述总结了2021年至2022年SLE的最新研究数据和成果，对过去两年开展的相关研究进行了概述和总结。
相似文献
1
[Research progress in systemic lupus erythematosus from 2021 to 2022].[2021年至2022年系统性红斑狼疮的研究进展]
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Aug 15;25(8):785-790. doi: 10.7499/j.issn.1008-8830.2302150.
2
Diagnostic and prognostic tests in systemic lupus erythematosus.系统性红斑狼疮的诊断和预后测试
Best Pract Res Clin Rheumatol. 2017 Jun;31(3):351-363. doi: 10.1016/j.berh.2017.10.002. Epub 2017 Nov 6.
3
Organ-specific biomarkers in lupus.狼疮中的器官特异性生物标志物。
Autoimmun Rev. 2017 Apr;16(4):391-397. doi: 10.1016/j.autrev.2017.02.011. Epub 2017 Feb 14.
4
The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus.系统性红斑狼疮的发病机制：利用大数据理解狼疮的分子基础。
J Autoimmun. 2020 Jun;110:102359. doi: 10.1016/j.jaut.2019.102359. Epub 2019 Dec 2.
5
Systemic lupus erythematosus: year in review 2019.系统性红斑狼疮：2019年回顾
Chin Med J (Engl). 2020 Sep 20;133(18):2189-2196. doi: 10.1097/CM9.0000000000000983.
6
Biomarkers for systemic lupus erythematosus - a focus on organ damage.系统性红斑狼疮的生物标志物 - 关注器官损伤。
Expert Rev Clin Immunol. 2024 Jan-Jun;20(1):39-58. doi: 10.1080/1744666X.2023.2260098. Epub 2023 Sep 15.
7
TMT-based quantitative proteomics analysis and potential serum protein biomarkers for systemic lupus erythematosus.基于 TMT 的定量蛋白质组学分析及系统性红斑狼疮的潜在血清蛋白标志物。
Clin Chim Acta. 2022 Sep 1;534:43-49. doi: 10.1016/j.cca.2022.06.031. Epub 2022 Jul 8.
8
The applied basic research of systemic lupus erythematosus based on the biological omics.基于生物组学的系统性红斑狼疮应用基础研究。
Genes Immun. 2013 Apr;14(3):133-46. doi: 10.1038/gene.2013.3. Epub 2013 Feb 28.
9
Systemic lupus erythematosus: a review of the disease and treatment options.系统性红斑狼疮：疾病及治疗选择综述
Consult Pharm. 2013 Feb;28(2):110-21. doi: 10.4140/TCP.n.2013.110.
10
[Unmet needs in systemic lupus erythematosus].[系统性红斑狼疮未满足的需求]
Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(6):396-407. doi: 10.2177/jsci.40.396.
引用本文的文献
1
Mechanism of action of lncRNA-NEAT1 in immune diseases.长链非编码RNA-NEAT1在免疫疾病中的作用机制。
Front Genet. 2025 Mar 5;16:1501115. doi: 10.3389/fgene.2025.1501115. eCollection 2025.
2
Relationship between clinical manifestations and serological profile in patients affected by Systemic Lupus Erythematosus.系统性红斑狼疮患者的临床表现与血清学特征的关系。
Front Immunol. 2024 Aug 16;15:1390642. doi: 10.3389/fimmu.2024.1390642. eCollection 2024.
本文引用的文献
1
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.I型干扰素抑制剂阿尼鲁单抗治疗活动性系统性红斑狼疮（TULIP-1）：一项随机、对照、3期试验
Lancet Rheumatol. 2019 Dec;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1. Epub 2019 Nov 11.
2
Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity.IL-2 与 IL-2Rα 的临近效应共价结合，选择性地激活调节性 T 细胞并抑制自身免疫。
Signal Transduct Target Ther. 2023 Jan 23;8(1):28. doi: 10.1038/s41392-022-01208-3.
3
Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus.针对 I 型干扰素的抗体：系统性红斑狼疮中自我抑制的“坏家伙”。
Cell Rep Med. 2023 Jan 17;4(1):100903. doi: 10.1016/j.xcrm.2022.100903.
4
Engineered Cell Membrane Vesicles Expressing CD40 Alleviate System Lupus Nephritis by Intervening B Cell Activation.表达CD40的工程化细胞膜囊泡通过干预B细胞活化减轻系统性红斑狼疮肾炎
Small Methods. 2023 Mar;7(3):e2200925. doi: 10.1002/smtd.202200925. Epub 2023 Jan 5.
5
Amelioration of Autoimmunity in a Lupus Mouse Model by Modulation of T-Bet-Promoted Energy Metabolism in Pathogenic Age/Autoimmune-Associated B Cells.通过调节致病性年龄/自身免疫相关 B 细胞中 T 细胞生成素促进的能量代谢来改善狼疮小鼠模型中的自身免疫。
Arthritis Rheumatol. 2023 Jul;75(7):1203-1215. doi: 10.1002/art.42433. Epub 2023 May 17.
6
Research advances on targeted-Treg therapies on immune-mediated kidney diseases.靶向调节性 T 细胞治疗免疫介导性肾脏疾病的研究进展。
Autoimmun Rev. 2023 Feb;22(2):103257. doi: 10.1016/j.autrev.2022.103257. Epub 2022 Dec 20.
7
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.德夸西替尼，一种酪氨酸激酶 2 抑制剂，在系统性红斑狼疮中的应用：一项 II 期、随机、双盲、安慰剂对照试验。
Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11.
8
Clinical Implications of a New DDX58 Pathogenic Variant That Causes Lupus Nephritis due to RIG-I Hyperactivation.一种新的 DDX58 致病性变异导致 RIG-I 过度激活引发狼疮肾炎的临床意义。
J Am Soc Nephrol. 2023 Feb 1;34(2):258-272. doi: 10.1681/ASN.2022040477. Epub 2022 Oct 19.
9
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.系统性红斑狼疮的全球流行病学：全面系统分析和建模研究。
Ann Rheum Dis. 2023 Mar;82(3):351-356. doi: 10.1136/ard-2022-223035. Epub 2022 Oct 14.
10
Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17 regulatory T cell.间充质干细胞衍生的外泌体诱导的巨噬细胞通过促进吞噬作用和募集 IL-17 调节性 T 细胞缓解系统性红斑狼疮。
Stem Cell Res Ther. 2022 Sep 24;13(1):484. doi: 10.1186/s13287-022-03174-7.
Zotero 插件